Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Edwards PASCAL System
- device: Abbott Mitraclip System
Eligibility
Inclusion Criteria:
- Eighteen (18) years of age or older
- Patient is able and willing to give informed consent and follow protocol procedures,
and comply with follow-up visit requirements.
- Patient is determined to be at prohibitive risk for mitral valve surgery by the heart
team (CLASP IID cohort only).
- Patient is on stable heart failure medications/Guideline Directed Medical Therapy
(CLASP IIF cohort only)
- Patient is determined to be a candidate for transcatheter mitral valve repair by the
heart team for both PASCAL and MitraClip
- Mitral regurgitation (3+ to 4+) by echo
- Suitable valve and regurgitant jet morphology
- Elevated corrected BNP > 400 pg/ml or corrected NT-pro BNP of > 900 pg/ml or heart
failure hospitalization within the past 12 months (CLASP IIF cohort only)
- LVEF ≥ 20% (and ≤ 50%; CLASP IIF cohort only)
Exclusion Criteria:
- Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
- Mitral valve anatomy which may preclude proper PASCAL or MitraClip access, use and/or
deployment or sufficient reduction in mitral regurgitation
- Patient with refractory heart failure requiring advanced intervention (i.e. left
ventricular assist device, Status ≤5 heart transplantation) (ACC/AHA Stage D heart
failure)
- Clinically significant, untreated coronary artery disease
- Recent stroke
- Other severe valve disorders requiring intervention
- Need for emergent or urgent surgery for any reason or any planned cardiac surgery
within the next 12 months
- Any prior mitral valve surgery or transcatheter mitral valve procedure (excluding
chordal replacement or surgical annuloplasty repair)
- Severe tricuspid regurgitation or tricuspid valve disease requiring surgery
- Active rheumatic heart disease or rheumatic etiology for MR
- Severe aortic stenosis or regurgitation
- Known history of untreated, severe carotid stenosis
- Recent deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Severe COPD
- Pregnant or planning pregnancy within next 12 months. Note: Female patients of
childbearing potential need to have a negative pregnancy test performed within 14 days
prior to intervention and be adherent to an accepted method of contraception
- Concurrent medical condition with a life expectancy of less than 12 months in the
judgment of the Investigator
- Patient is currently participating in another investigational biologic, drug or device
clinical study where the primary study endpoint was not reached at time of enrollment
- Other medical, social, or psychological conditions that preclude appropriate consent
and follow-up, including patients under guardianship
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Edwards PASCAL System
- device: Abbott Mitraclip System
Eligibility
Inclusion Criteria:
- Eighteen (18) years of age or older
- Patient is able and willing to give informed consent and follow protocol procedures,
and comply with follow-up visit requirements.
- Patient is determined to be at prohibitive risk for mitral valve surgery by the heart
team (CLASP IID cohort only).
- Patient is on stable heart failure medications/Guideline Directed Medical Therapy
(CLASP IIF cohort only)
- Patient is determined to be a candidate for transcatheter mitral valve repair by the
heart team for both PASCAL and MitraClip
- Mitral regurgitation (3+ to 4+) by echo
- Suitable valve and regurgitant jet morphology
- Elevated corrected BNP > 400 pg/ml or corrected NT-pro BNP of > 900 pg/ml or heart
failure hospitalization within the past 12 months (CLASP IIF cohort only)
- LVEF ≥ 20% (and ≤ 50%; CLASP IIF cohort only)
Exclusion Criteria:
- Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
- Mitral valve anatomy which may preclude proper PASCAL or MitraClip access, use and/or
deployment or sufficient reduction in mitral regurgitation
- Patient with refractory heart failure requiring advanced intervention (i.e. left
ventricular assist device, Status ≤5 heart transplantation) (ACC/AHA Stage D heart
failure)
- Clinically significant, untreated coronary artery disease
- Recent stroke
- Other severe valve disorders requiring intervention
- Need for emergent or urgent surgery for any reason or any planned cardiac surgery
within the next 12 months
- Any prior mitral valve surgery or transcatheter mitral valve procedure (excluding
chordal replacement or surgical annuloplasty repair)
- Severe tricuspid regurgitation or tricuspid valve disease requiring surgery
- Active rheumatic heart disease or rheumatic etiology for MR
- Severe aortic stenosis or regurgitation
- Known history of untreated, severe carotid stenosis
- Recent deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Severe COPD
- Pregnant or planning pregnancy within next 12 months. Note: Female patients of
childbearing potential need to have a negative pregnancy test performed within 14 days
prior to intervention and be adherent to an accepted method of contraception
- Concurrent medical condition with a life expectancy of less than 12 months in the
judgment of the Investigator
- Patient is currently participating in another investigational biologic, drug or device
clinical study where the primary study endpoint was not reached at time of enrollment
- Other medical, social, or psychological conditions that preclude appropriate consent
and follow-up, including patients under guardianship
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Edwards PASCAL System
- device: Abbott Mitraclip System
Eligibility
Inclusion Criteria:
- Eighteen (18) years of age or older
- Patient is able and willing to give informed consent and follow protocol procedures,
and comply with follow-up visit requirements.
- Patient is determined to be at prohibitive risk for mitral valve surgery by the heart
team (CLASP IID cohort only).
- Patient is on stable heart failure medications/Guideline Directed Medical Therapy
(CLASP IIF cohort only)
- Patient is determined to be a candidate for transcatheter mitral valve repair by the
heart team for both PASCAL and MitraClip
- Mitral regurgitation (3+ to 4+) by echo
- Suitable valve and regurgitant jet morphology
- Elevated corrected BNP > 400 pg/ml or corrected NT-pro BNP of > 900 pg/ml or heart
failure hospitalization within the past 12 months (CLASP IIF cohort only)
- LVEF ≥ 20% (and ≤ 50%; CLASP IIF cohort only)
Exclusion Criteria:
- Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
- Mitral valve anatomy which may preclude proper PASCAL or MitraClip access, use and/or
deployment or sufficient reduction in mitral regurgitation
- Patient with refractory heart failure requiring advanced intervention (i.e. left
ventricular assist device, Status ≤5 heart transplantation) (ACC/AHA Stage D heart
failure)
- Clinically significant, untreated coronary artery disease
- Recent stroke
- Other severe valve disorders requiring intervention
- Need for emergent or urgent surgery for any reason or any planned cardiac surgery
within the next 12 months
- Any prior mitral valve surgery or transcatheter mitral valve procedure (excluding
chordal replacement or surgical annuloplasty repair)
- Severe tricuspid regurgitation or tricuspid valve disease requiring surgery
- Active rheumatic heart disease or rheumatic etiology for MR
- Severe aortic stenosis or regurgitation
- Known history of untreated, severe carotid stenosis
- Recent deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Severe COPD
- Pregnant or planning pregnancy within next 12 months. Note: Female patients of
childbearing potential need to have a negative pregnancy test performed within 14 days
prior to intervention and be adherent to an accepted method of contraception
- Concurrent medical condition with a life expectancy of less than 12 months in the
judgment of the Investigator
- Patient is currently participating in another investigational biologic, drug or device
clinical study where the primary study endpoint was not reached at time of enrollment
- Other medical, social, or psychological conditions that preclude appropriate consent
and follow-up, including patients under guardianship
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Edwards PASCAL System
- device: Abbott Mitraclip System
Eligibility
Inclusion Criteria:
- Eighteen (18) years of age or older
- Patient is able and willing to give informed consent and follow protocol procedures,
and comply with follow-up visit requirements.
- Patient is determined to be at prohibitive risk for mitral valve surgery by the heart
team (CLASP IID cohort only).
- Patient is on stable heart failure medications/Guideline Directed Medical Therapy
(CLASP IIF cohort only)
- Patient is determined to be a candidate for transcatheter mitral valve repair by the
heart team for both PASCAL and MitraClip
- Mitral regurgitation (3+ to 4+) by echo
- Suitable valve and regurgitant jet morphology
- Elevated corrected BNP > 400 pg/ml or corrected NT-pro BNP of > 900 pg/ml or heart
failure hospitalization within the past 12 months (CLASP IIF cohort only)
- LVEF ≥ 20% (and ≤ 50%; CLASP IIF cohort only)
Exclusion Criteria:
- Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
- Mitral valve anatomy which may preclude proper PASCAL or MitraClip access, use and/or
deployment or sufficient reduction in mitral regurgitation
- Patient with refractory heart failure requiring advanced intervention (i.e. left
ventricular assist device, Status ≤5 heart transplantation) (ACC/AHA Stage D heart
failure)
- Clinically significant, untreated coronary artery disease
- Recent stroke
- Other severe valve disorders requiring intervention
- Need for emergent or urgent surgery for any reason or any planned cardiac surgery
within the next 12 months
- Any prior mitral valve surgery or transcatheter mitral valve procedure (excluding
chordal replacement or surgical annuloplasty repair)
- Severe tricuspid regurgitation or tricuspid valve disease requiring surgery
- Active rheumatic heart disease or rheumatic etiology for MR
- Severe aortic stenosis or regurgitation
- Known history of untreated, severe carotid stenosis
- Recent deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Severe COPD
- Pregnant or planning pregnancy within next 12 months. Note: Female patients of
childbearing potential need to have a negative pregnancy test performed within 14 days
prior to intervention and be adherent to an accepted method of contraception
- Concurrent medical condition with a life expectancy of less than 12 months in the
judgment of the Investigator
- Patient is currently participating in another investigational biologic, drug or device
clinical study where the primary study endpoint was not reached at time of enrollment
- Other medical, social, or psychological conditions that preclude appropriate consent
and follow-up, including patients under guardianship
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Edwards PASCAL System
- device: Abbott Mitraclip System
Eligibility
Inclusion Criteria:
- Eighteen (18) years of age or older
- Patient is able and willing to give informed consent and follow protocol procedures,
and comply with follow-up visit requirements.
- Patient is determined to be at prohibitive risk for mitral valve surgery by the heart
team (CLASP IID cohort only).
- Patient is on stable heart failure medications/Guideline Directed Medical Therapy
(CLASP IIF cohort only)
- Patient is determined to be a candidate for transcatheter mitral valve repair by the
heart team for both PASCAL and MitraClip
- Mitral regurgitation (3+ to 4+) by echo
- Suitable valve and regurgitant jet morphology
- Elevated corrected BNP > 400 pg/ml or corrected NT-pro BNP of > 900 pg/ml or heart
failure hospitalization within the past 12 months (CLASP IIF cohort only)
- LVEF ≥ 20% (and ≤ 50%; CLASP IIF cohort only)
Exclusion Criteria:
- Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
- Mitral valve anatomy which may preclude proper PASCAL or MitraClip access, use and/or
deployment or sufficient reduction in mitral regurgitation
- Patient with refractory heart failure requiring advanced intervention (i.e. left
ventricular assist device, Status ≤5 heart transplantation) (ACC/AHA Stage D heart
failure)
- Clinically significant, untreated coronary artery disease
- Recent stroke
- Other severe valve disorders requiring intervention
- Need for emergent or urgent surgery for any reason or any planned cardiac surgery
within the next 12 months
- Any prior mitral valve surgery or transcatheter mitral valve procedure (excluding
chordal replacement or surgical annuloplasty repair)
- Severe tricuspid regurgitation or tricuspid valve disease requiring surgery
- Active rheumatic heart disease or rheumatic etiology for MR
- Severe aortic stenosis or regurgitation
- Known history of untreated, severe carotid stenosis
- Recent deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Severe COPD
- Pregnant or planning pregnancy within next 12 months. Note: Female patients of
childbearing potential need to have a negative pregnancy test performed within 14 days
prior to intervention and be adherent to an accepted method of contraception
- Concurrent medical condition with a life expectancy of less than 12 months in the
judgment of the Investigator
- Patient is currently participating in another investigational biologic, drug or device
clinical study where the primary study endpoint was not reached at time of enrollment
- Other medical, social, or psychological conditions that preclude appropriate consent
and follow-up, including patients under guardianship
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Edwards PASCAL System
- device: Abbott Mitraclip System
Eligibility
Inclusion Criteria:
- Eighteen (18) years of age or older
- Patient is able and willing to give informed consent and follow protocol procedures,
and comply with follow-up visit requirements.
- Patient is determined to be at prohibitive risk for mitral valve surgery by the heart
team (CLASP IID cohort only).
- Patient is on stable heart failure medications/Guideline Directed Medical Therapy
(CLASP IIF cohort only)
- Patient is determined to be a candidate for transcatheter mitral valve repair by the
heart team for both PASCAL and MitraClip
- Mitral regurgitation (3+ to 4+) by echo
- Suitable valve and regurgitant jet morphology
- Elevated corrected BNP > 400 pg/ml or corrected NT-pro BNP of > 900 pg/ml or heart
failure hospitalization within the past 12 months (CLASP IIF cohort only)
- LVEF ≥ 20% (and ≤ 50%; CLASP IIF cohort only)
Exclusion Criteria:
- Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
- Mitral valve anatomy which may preclude proper PASCAL or MitraClip access, use and/or
deployment or sufficient reduction in mitral regurgitation
- Patient with refractory heart failure requiring advanced intervention (i.e. left
ventricular assist device, Status ≤5 heart transplantation) (ACC/AHA Stage D heart
failure)
- Clinically significant, untreated coronary artery disease
- Recent stroke
- Other severe valve disorders requiring intervention
- Need for emergent or urgent surgery for any reason or any planned cardiac surgery
within the next 12 months
- Any prior mitral valve surgery or transcatheter mitral valve procedure (excluding
chordal replacement or surgical annuloplasty repair)
- Severe tricuspid regurgitation or tricuspid valve disease requiring surgery
- Active rheumatic heart disease or rheumatic etiology for MR
- Severe aortic stenosis or regurgitation
- Known history of untreated, severe carotid stenosis
- Recent deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Severe COPD
- Pregnant or planning pregnancy within next 12 months. Note: Female patients of
childbearing potential need to have a negative pregnancy test performed within 14 days
prior to intervention and be adherent to an accepted method of contraception
- Concurrent medical condition with a life expectancy of less than 12 months in the
judgment of the Investigator
- Patient is currently participating in another investigational biologic, drug or device
clinical study where the primary study endpoint was not reached at time of enrollment
- Other medical, social, or psychological conditions that preclude appropriate consent
and follow-up, including patients under guardianship
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting